RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill shows promise for Hard-to-Treat lung cancer subtype
Disease control OngoingThis phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…
Matched conditions: RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets rare lung cancer mutation in advanced disease
Disease control OngoingThis phase II trial tests the drug selpercatinib (LOXO-292) in 124 people with stage IV or recurrent non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking enzymes that help cancer cells grow. Researchers are measuring how ma…
Matched conditions: RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lung cancer patients: drug may delay return of disease
Disease control OngoingThis study tests whether the drug selpercatinib can delay the return of lung cancer in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants have already had surgery or radiation to remove or treat their cancer. They will…
Matched conditions: RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC